A Howe

1.7k total citations
35 papers, 978 citations indexed

About

A Howe is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, A Howe has authored 35 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hepatology, 22 papers in Infectious Diseases and 20 papers in Epidemiology. Recurrent topics in A Howe's work include Hepatitis C virus research (30 papers), Hepatitis B Virus Studies (20 papers) and HIV/AIDS drug development and treatment (20 papers). A Howe is often cited by papers focused on Hepatitis C virus research (30 papers), Hepatitis B Virus Studies (20 papers) and HIV/AIDS drug development and treatment (20 papers). A Howe collaborates with scholars based in United States, Canada and Japan. A Howe's co-authors include Tara L. Kieffer, Edward Tam, Johan Lennerstrand, Neil Parkin, Patrick R. Harrington, Veronica Miller, Oliver Lenz, Fiona McPhee, Hongmei Mo and Erik Lontok and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

A Howe

34 papers receiving 955 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A Howe United States 15 878 754 434 87 54 35 978
Giulia Morsica Italy 18 1.1k 1.3× 1.0k 1.3× 241 0.6× 69 0.8× 96 1.8× 73 1.3k
Thierry Verbinnen Belgium 15 919 1.0× 841 1.1× 381 0.9× 84 1.0× 59 1.1× 39 1.0k
Hyunsoon Kang United States 9 649 0.7× 495 0.7× 451 1.0× 173 2.0× 18 0.3× 11 795
Ann M. Tigges United States 9 700 0.8× 541 0.7× 397 0.9× 51 0.6× 49 0.9× 14 722
Michelle Irvin United States 11 583 0.7× 479 0.6× 305 0.7× 54 0.6× 32 0.6× 17 665
Ross Martin United States 21 907 1.0× 860 1.1× 713 1.6× 122 1.4× 43 0.8× 56 1.3k
Isla Humphreys United Kingdom 8 1.4k 1.6× 1.3k 1.7× 266 0.6× 132 1.5× 65 1.2× 11 1.6k
Sue Ma United States 8 540 0.6× 379 0.5× 230 0.5× 201 2.3× 39 0.7× 11 709
Minoru Sakamoto Japan 16 458 0.5× 440 0.6× 127 0.3× 63 0.7× 43 0.8× 28 659
Bart Fevery United States 15 928 1.1× 849 1.1× 317 0.7× 31 0.4× 74 1.4× 35 949

Countries citing papers authored by A Howe

Since Specialization
Citations

This map shows the geographic impact of A Howe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Howe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Howe more than expected).

Fields of papers citing papers by A Howe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A Howe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Howe. The network helps show where A Howe may publish in the future.

Co-authorship network of co-authors of A Howe

This figure shows the co-authorship network connecting the top 25 collaborators of A Howe. A scholar is included among the top collaborators of A Howe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A Howe. A Howe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Montoya, Vincent, A Howe, Winnie Dong, et al.. (2021). Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs. Scientific Reports. 11(1). 9986–9986.
2.
Olmstead, Andrea D., Vincent Montoya, Celia Chui, et al.. (2019). A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. Infection Genetics and Evolution. 69. 76–84. 6 indexed citations
3.
Cento, Valeria, Velia Chiara Di Maio, A Howe, et al.. (2018). Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resistance Updates. 37. 17–39. 136 indexed citations
4.
Jones, Bradley R., A Howe, P. Richard Harrigan, & Jeffrey B. Joy. (2017). The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus. Virus Evolution. 4(1). vex041–vex041. 5 indexed citations
5.
Süsser, S., Julia Dietz, Bernhard Schlevogt, et al.. (2017). Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. Journal of Hepatology. 67(4). 680–686. 20 indexed citations
6.
Ludmerer, Steven W., Stuart Black, A Howe, et al.. (2016). HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials. Antiviral Research. 130. 118–129. 2 indexed citations
7.
Gane, Edward, Ziv Ben Ari, Lindsay Mollison, et al.. (2016). Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1 infection. Journal of Viral Hepatitis. 23(10). 789–797. 9 indexed citations
8.
Forns, Xavier, Stuart C. Gordon, Eli Zuckerman, et al.. (2015). Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. Journal of Hepatology. 63(3). 564–572. 109 indexed citations
9.
Hayashi, Norio, Makoto Nakamuta, Tetsuo Takehara, et al.. (2015). Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. Journal of Gastroenterology. 51(4). 390–403. 15 indexed citations
10.
Brown, Ashley, Christophe Hézode, Eli Zuckerman, et al.. (2015). P0771 : C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/- elbasvir +/- ribavirin in patients with HCV GT2, 4, 5 or 6 infection. Journal of Hepatology. 62. S619–S619. 12 indexed citations
11.
Lontok, Erik, Patrick R. Harrington, A Howe, et al.. (2015). Hepatitis C virus drug resistance–associated substitutions: State of the art summary. Hepatology. 62(5). 1623–1632. 217 indexed citations
12.
Howe, A, Stuart Black, Stephanie Curry, et al.. (2014). Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection. Clinical Infectious Diseases. 59(12). 1657–1665. 33 indexed citations
13.
McGivern, David R., Takahiro Masaki, Paul Ingravallo, et al.. (2014). Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors. Gastroenterology. 147(2). 453–462.e7. 84 indexed citations
14.
Manns, Michael P., John M. Vierling, Bruce R. Bacon, et al.. (2014). The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. Gastroenterology. 147(2). 366–376.e6. 28 indexed citations
15.
16.
Howe, John A., Donald J. Graham, Patricia McMonagle, et al.. (2012). 844 IN VITRO CHARACTERIZATION OF THE PAN-GENOTYPE ACTIVITY OF THE HCV NS3/4A PROTEASE INHIBITORS BOCEPREVIR AND TELAPREVIR. Journal of Hepatology. 56. S329–S329. 2 indexed citations
17.
Howe, A, et al.. (2011). Quantitation of Amyloid Beta Peptides in CSF by Surface Enhanced MALDI-TOF. Methods in molecular biology. 818. 227–236. 3 indexed citations
18.
Howe, A, Robert A. Chase, S. Shane Taremi, et al.. (1999). A novel recombinant single‐chain hepatitis C virus ns3‐ns4a protein with improved helicase activity. Protein Science. 8(6). 1332–1341. 44 indexed citations
19.
20.
Howe, A, John F. Elliott, & David Tyrrell. (1992). Duck Hepatitis B Virus polymerase produced by in vitro transcription and translation possesses DNA polymerase and reverse transcriptase activities. Biochemical and Biophysical Research Communications. 189(2). 1170–1176. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giulia Morsica Breakdown of academic impact, for papers by Thierry Verbinnen Breakdown of academic impact, for papers by Hyunsoon Kang Breakdown of academic impact, for papers by Ann M. Tigges Breakdown of academic impact, for papers by Michelle Irvin Breakdown of academic impact, for papers by Ross Martin Breakdown of academic impact, for papers by Isla Humphreys Breakdown of academic impact, for papers by Sue Ma Breakdown of academic impact, for papers by Minoru Sakamoto Breakdown of academic impact, for papers by Bart Fevery
Rankless by CCL
2026